-
Study aim
-
Effect of N-acetyl cysteine on the expression of Oxidation-Reduction genes of (NRF1, NRF2, GPX3, PRDX6, FKBP4, and MTHFR) during implantation window in women with Recurrent Implantation Failure
-
Design
-
A Randomized, Placebo-Controlled, patient and assessor blinded, Phase 2 Clinical Trial
-
Settings and conduct
-
Forty infertile women with a diagnosis of RIF referred to Royan Institute, will be included in this study and randomly will be divided into intervention and control groups. At the first step, they will be received 1200 mg of effervescent tablets of N-acetyl cysteine (NAC) daily or placebo about 6 weeks. The endometrial biopsy will be taken from patients by catheter biopsy (Pipelle) on 19-21th day in the cycle prior to IVF transfer procedure. In next cycle, these women will undergo routine infertile treatment and ovulation stimulation for IVF procedure and they will continue to take NAC or placebo.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: age between 20 and 40 years old; at least twice implantation failure; BMI in the normal range. Patients prescribed drugs such as folic acid, iron, multivitamins, and supplements generally equal status.
Exclusion criteria: Irregular menstrual cycle, taking hormonal drugs except thyroid medication, patients with abnormal karyotype or chromosomal disorders; patients who have coagulation problems.
-
Intervention groups
-
Intervention group: receive 1200 mg of effervescent tablets of N-acetyl cysteine (NAC) daily about 6 weeks.
Control group: receive 1200 mg of effervescent tablets of placebo daily about 6 weeks.
-
Main outcome variables
-
Evaluation of Gene expression related to implantation